{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:44:19Z","timestamp":1785717859716,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102698"],"award-info":[{"award-number":["82102698"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Medical Association Clinical Research Fund - Qilu Special Project","award":["YXH2022ZX02037"],"award-info":[{"award-number":["YXH2022ZX02037"]}]},{"name":"the Key Research and Development Program of Dezhou in 2024","award":["No.13"],"award-info":[{"award-number":["No.13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While the synaptic vesicle protein SYNGR4 has established roles in the pathobiology of motor neuron disease, its comprehensive oncogenic significance across diverse cancers, and its specific value as a clinical biomarker and therapeutic target in lung adenocarcinoma (LUAD), are entirely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our pan-cancer multi-omics analysis systematically assessed the expression, prognostic value, prognostic nomogram models, and clinical correlates of SYNGR4, investigated its DNA methylation, genetic alterations, and functional pathways (GO\/KEGG\/GSEA), and evaluated its associations with immune infiltration, immunotherapy response, and drug sensitivity across various cancer types. In addition, we performed qPCR, CCK-8, colony formation, EdU staining, and wound-healing analyses to elucidate the role of SYNGR4 in LUAD proliferation and migration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our pan-cancer multi-omics results indicate that SYNGR4 is upregulated in multiple cancers and correlates with prognosis. Its expression was linked to DNA methylation, immune cell infiltration and improved responses to PD-1 blockade (nivolumab) and anti-PD-L1 therapy. SYNGR4 expression also showed positive correlations with sensitivity to MEK inhibitors (PD-0325901, Trametinib) and Docetaxel. Pathway analysis linked SYNGR4 to cell cycle progression and synthesis of DNA. In addition, knockdown of SYNGR4 via siRNA suppressed the proliferative and migratory capacities of LUAD cells in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study establishes SYNGR4 as a novel prognostic biomarker in LUAD, thereby positioning it as a potential therapeutic target with clinical utility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-026-05319-z","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:46:43Z","timestamp":1780120003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pan-cancer multi-omics analysis identifies SYNGR4 as a novel clinical prognostic biomarker and therapeutic target in lung adenocarcinoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Yanjiao","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"1","key":"5319_CR1","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S1470-2045(24)00522-9","volume":"26","author":"R Casolino","year":"2025","unstructured":"Casolino R, Sullivan R, Jobanputra K, Abdel-Wahab M, Grbic M, Hammad N, Kutluk T, Melnitchouk N, Mueller A, Ortiz R, et al. Integrating cancer into crisis: a global vision for action from WHO and partners. Lancet Oncol. 2025;26(1):e55\u201366.","journal-title":"Lancet Oncol"},{"key":"5319_CR2","doi-asserted-by":"publisher","first-page":"122432","DOI":"10.1016\/j.biomaterials.2023.122432","volume":"305","author":"X Li","year":"2024","unstructured":"Li X, Jin K, Cheng TC, Liao YC, Lee WJ, Bhullar AS, Chen LC, Rychahou P, Phelps MA, Ho YS, et al. RNA four-way junction (4WJ) for spontaneous cancer-targeting, effective tumor-regression, metastasis suppression, fast renal excretion and undetectable toxicity. Biomaterials. 2024;305:122432.","journal-title":"Biomaterials"},{"key":"5319_CR3","doi-asserted-by":"publisher","first-page":"900273","DOI":"10.3389\/fimmu.2022.900273","volume":"13","author":"X Han","year":"2022","unstructured":"Han X, Ye J, Huang R, Li Y, Liu J, Meng T, Song D. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect. Front Immunol. 2022;13:900273.","journal-title":"Front Immunol"},{"issue":"13","key":"5319_CR4","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1056\/NEJMcibr2110552","volume":"385","author":"R Bose","year":"2021","unstructured":"Bose R, Ma CX. Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance. N Engl J Med. 2021;385(13):1241\u20133.","journal-title":"N Engl J Med"},{"issue":"16","key":"5319_CR5","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1093\/hmg\/ddaa140","volume":"29","author":"RF Marques","year":"2020","unstructured":"Marques RF, Engler JB, K\u00fcchler K, Jones RA, Lingner T, Salinas G, Gillingwater TH, Friese MA, Duncan KE. Motor neuron translatome reveals deregulation of SYNGR4 and PLEKHB1 in mutant TDP-43 amyotrophic lateral sclerosis models. Hum Mol Genet. 2020;29(16):2647\u201361.","journal-title":"Hum Mol Genet"},{"key":"5319_CR6","doi-asserted-by":"publisher","first-page":"1490073","DOI":"10.3389\/fonc.2024.1490073","volume":"14","author":"J Ma","year":"2024","unstructured":"Ma J, Wang H, Gui Z, Yang Y. Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy. Front Oncol. 2024;14:1490073.","journal-title":"Front Oncol"},{"issue":"12","key":"5319_CR7","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1080\/15384101.2023.2216504","volume":"22","author":"B Yu","year":"2023","unstructured":"Yu B, Zhou Y, He J. TRIM13 inhibits cell proliferation and induces autophagy in lung adenocarcinoma by regulating KEAP1\/NRF2 pathway. Cell Cycle. 2023;22(12):1496\u2013513.","journal-title":"Cell Cycle"},{"key":"5319_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.neuroscience.2024.11.081","volume":"565","author":"KI Gidado","year":"2025","unstructured":"Gidado KI, Adeshakin FO, Rabiu L, Zhang Z, Zhang G, Wan X. Multifaceted roles of DLG3\/SAP102 in neurophysiology, neurological disorders and tumorigenesis. Neuroscience. 2025;565:192\u2013201.","journal-title":"Neuroscience"},{"issue":"7","key":"5319_CR9","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/s41416-022-01863-x","volume":"127","author":"J Li","year":"2022","unstructured":"Li J, Xu Y, Zhu H, Wang Y, Li P, Wang D. The dark side of synaptic proteins in tumours. Br J Cancer. 2022;127(7):1184\u201392.","journal-title":"Br J Cancer"},{"issue":"10","key":"5319_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113\u201320.","journal-title":"Nat Genet"},{"issue":"6","key":"5319_CR11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"G Consortium","year":"2013","unstructured":"Consortium G. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580\u20135.","journal-title":"Nat Genet"},{"issue":"6","key":"5319_CR12","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1053\/j.gastro.2023.12.016","volume":"166","author":"N Forbes","year":"2024","unstructured":"Forbes N. RNA-Based Stool Molecular Testing-A Novel Potential Option for Colorectal Cancer Screening. Gastroenterology. 2024;166(6):1190.","journal-title":"Gastroenterology"},{"key":"5319_CR13","doi-asserted-by":"crossref","unstructured":"Jenny K, Mayen B, Aditi V, David G. Clonal evolution and therapy resistance in the era of precision cancer medicine: evolutionary trajectories in pediatric cancer. Semin Cancer Biol. 2025;116(0):1\u201314.","DOI":"10.1016\/j.semcancer.2025.10.001"},{"key":"5319_CR14","doi-asserted-by":"publisher","first-page":"10248","DOI":"10.1021\/acs.chemrev.5c00041","volume":"125","author":"K Jia Xuan","year":"2025","unstructured":"Jia Xuan K, Jia Ning Nicolette Y, Ram Pravin KM, Xinyi W, Wei Heng C, Alvaro L-S, Kevin Kuang Wei T, Lih-Wen D, Dan G, Helene CB, et al. Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs. Chem Rev. 2025;125:10248\u2013341.","journal-title":"Chem Rev"},{"key":"5319_CR15","doi-asserted-by":"crossref","unstructured":"Jian Z, Zhaozhou R, Haibo W, Xing Y, Yang S, Jun L, Xiaoying L. Emerging Nanozyme Strategies for Precision Breast Cancer Treatment. Adv Sci (Weinh). 2025;12:e14085.","DOI":"10.1002\/advs.202514085"},{"issue":"1","key":"5319_CR16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41392-025-02321-9","volume":"10","author":"W Qi","year":"2025","unstructured":"Qi W, Juan L, Ming Y, Jun Z, Yaxuan L, Jingjing Z, Hao J, Shuhua Y, Yinpeng L, Yuxin S, et al. Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma. Signal Transduct Target Ther. 2025;10(1):244.","journal-title":"Signal Transduct Target Ther"},{"key":"5319_CR17","first-page":"10512","volume":"406","author":"GCD Collaborators","year":"2025","unstructured":"Collaborators GCD. The global, regional, and national burden of cancer, 1990\u20132023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406:10512.","journal-title":"Lancet"},{"issue":"12","key":"5319_CR18","doi-asserted-by":"publisher","first-page":"11905","DOI":"10.1021\/acsnano.3c03512","volume":"17","author":"C Liu","year":"2023","unstructured":"Liu C, Xianyu B, Dai Y, Pan S, Li T, Xu H. Intracellular Hyperbranched Polymerization for Circumventing Cancer Drug Resistance. ACS Nano. 2023;17(12):11905\u201313.","journal-title":"ACS Nano"},{"issue":"34","key":"5319_CR19","doi-asserted-by":"publisher","first-page":"30758","DOI":"10.1021\/acsnano.5c07748","volume":"19","author":"MM Amanda","year":"2025","unstructured":"Amanda MM, Kelsey LS, Michael JM. Engineering Nanoparticles for Gynecologic Cancer Therapy. ACS Nano. 2025;19(34):30758\u201385.","journal-title":"ACS Nano"},{"key":"5319_CR20","doi-asserted-by":"crossref","unstructured":"Mingyang J, Jinlong W, Yize L, Ke Z, Tao W, Zhandong B, Shenyi L, Raquel Alarc\u00f3n R, Ruqiong W, Mingtao Z, et al. EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets. Drug Resist Updat. 2025;83:10276.","DOI":"10.1016\/j.drup.2025.101276"},{"issue":"1","key":"5319_CR21","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1038\/s41467-022-30342-3","volume":"13","author":"Z Yiqun","year":"2022","unstructured":"Yiqun Z, Fengju C, Darshan SC, Sooryanarayana V, Chad JC. Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. Nat Commun. 2022;13(1):2669.","journal-title":"Nat Commun"},{"issue":"2","key":"5319_CR22","first-page":"321","volume":"173","author":"S-V Francisco","year":"2018","unstructured":"Francisco S-V, Marco M, Joshua A, Walid KC, Augustin L, Konnor CL, Sofia D, David LL, Havish SK, Sadegh S, et al. Oncogenic Signal Pathways Cancer Genome Atlas Cell. 2018;173(2):321\u201337.","journal-title":"Oncogenic Signal Pathways Cancer Genome Atlas Cell"},{"key":"5319_CR23","first-page":"1","volume":"17","author":"H Syed","year":"2016","unstructured":"Syed H, Alan M, Ruud GPM, vS LMW, Simon W, Adrian LH. Francesca M B: Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. Genome Biol. 2016;17:1.","journal-title":"Genome Biol"},{"key":"5319_CR24","first-page":"1","volume":"16","author":"W Kathleen","year":"2025","unstructured":"Kathleen W, Bianca D, Krzysztof JS, Laura L, Predrag J, Shan C, Ranveer P, Julia AV, Tyler TC, David P, et al. Epigenetic alterations facilitate transcriptional and translational programs in hypoxia. Nat Cell Biol. 2025;16:1\u20137.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"5319_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41587-024-02213-3","volume":"43","author":"MP Naomi","year":"2024","unstructured":"Naomi MP, Zachary S, Quanming S, Julia AB, Dmytro D, Katerina K, Kevin RP, Brian RS, Alexander M, Howard YC. Bidirectional epigenetic editing reveals hierarchies in gene regulation. Nat Biotechnol. 2024;43(3):355\u201368.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"5319_CR26","first-page":"460","volume":"37","author":"L Kai","year":"2024","unstructured":"Kai L, Lulu W, Ranran W, Li L, Shiyu S, Fei W, Meiwei H, Wenyuan P, Jinglin W, Junaid W, et al. Disrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1. Cell Metab. 2024;37(2):460\u201376.","journal-title":"Cell Metab"},{"issue":"4","key":"5319_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.cmet.2025.01.002","volume":"37","author":"TBN Nguyen","year":"2025","unstructured":"Nguyen TBN, Sira G, Rutger NUK, Lotte MB, Hannah N, Ninouk A, Max AB, Marlies CL, Can G. Edwin C A S: Lactate controls cancer stemness and plasticity through epigenetic regulation. Cell Metab. 2025;37(4):903\u201319.","journal-title":"Cell Metab"},{"key":"5319_CR28","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.2147\/IJGM.S351168","volume":"15","author":"X Han","year":"2022","unstructured":"Han X, Song D. Using a Machine Learning Approach to Identify Key Biomarkers for Renal Clear Cell Carcinoma. Int J Gen Med. 2022;15:3541\u201358.","journal-title":"Int J Gen Med"},{"key":"5319_CR29","doi-asserted-by":"publisher","first-page":"1678907","DOI":"10.3389\/fimmu.2025.1678907","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lu K, Xu Y, Xu S, Chu H, Fang X. Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies. Front Immunol. 2025;16:1678907.","journal-title":"Front Immunol"},{"key":"5319_CR30","doi-asserted-by":"publisher","first-page":"1325262","DOI":"10.1155\/sci\/1325262","volume":"2025","author":"P Wang","year":"2025","unstructured":"Wang P, Xu S, Guo Q, Zhao Y. Discovery of PAK2 as a Key Regulator of Cancer Stem Cell in Head and Neck Squamous Cell Carcinoma Using Multi-Omic Techniques. Stem Cells Int. 2025;2025:1325262.","journal-title":"Stem Cells Int"},{"issue":"4","key":"5319_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jamaoncol.2025.6508","volume":"12","author":"S Xu","year":"2026","unstructured":"Xu S, Guo Q, Lu Z. Physical Activity, Lifestyle, and Cancer Risk. JAMA Oncol. 2026;12(4):425\u20136.","journal-title":"JAMA Oncol"},{"issue":"8","key":"5319_CR32","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"AH Michael","year":"2024","unstructured":"Michael AH, Peter S, Balaji V, Megan MROM, Jasmine K, Scott NM, Laura KM, Roberto S, Sherene L. Towards targeting the breast cancer immune microenvironment. Nat Rev Cancer. 2024;24(8):554\u201377.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"5319_CR33","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","volume":"41","author":"L Jianxia","year":"2023","unstructured":"Jianxia L, Cheng W, Huabin H, Ge Q, Xueqian W, Fan B, Jianwei Z, Yue C, Yan H, Chao W, et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell. 2023;41(6):1152\u201369.","journal-title":"Cancer Cell"},{"issue":"7","key":"5319_CR34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","volume":"20","author":"P Tri Giang","year":"2020","unstructured":"Tri Giang P, Peter IC. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20(7):398\u2013411.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5319_CR35","first-page":"30","volume":"32","author":"L Jing","year":"2021","unstructured":"Jing L, Yunhua P, Wenyi W. Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol. 2021;32(1):30\u201344.","journal-title":"Trends Cell Biol"},{"issue":"9","key":"5319_CR36","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.trecan.2022.04.006","volume":"8","author":"KW Agnieszka","year":"2022","unstructured":"Agnieszka KW, Vishnu K, Ioannis S, Erik SK. Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy. Trends Cancer. 2022;8(9):711\u201325.","journal-title":"Trends Cancer"},{"issue":"1","key":"5319_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41556-024-01565-x","volume":"27","author":"H Sol\u00e8ne","year":"2025","unstructured":"Sol\u00e8ne H, Andrea S, Gabriele BM, Marine G, Kotryna V, Marie D, Annapaola A, Adib K, Gianluca P, Mathieu D, et al. Chromosome mis-segregation triggers cell cycle arrest through a mechanosensitive nuclear envelope checkpoint. Nat Cell Biol. 2025;27(1):73\u201386.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"5319_CR38","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.7150\/thno.103722","volume":"15","author":"W Jingyi","year":"2025","unstructured":"Jingyi W, Liu L, Xinyu G, Xiyu L, Yitian D, Zijun M, Shengzhe H, Junjian L, Dongliang W, Yu Q, et al. A novel pathway for stemness propagation and chemoresistance in non-small cell lung cancer via phosphorylated PKM2-loaded small extracellular vesicles. Theranostics. 2025;15(8):3439.","journal-title":"Theranostics"},{"key":"5319_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.dnarep.2016.07.001","volume":"45","author":"EJ Steele","year":"2016","unstructured":"Steele EJ. Somatic hypermutation in immunity and cancer: Critical analysis of strand-biased and codon-context mutation signatures. DNA Repair (Amst). 2016;45:1\u201324.","journal-title":"DNA Repair (Amst)"},{"issue":"6","key":"5319_CR40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2174\/138920310791824075","volume":"11","author":"A Sivanandam","year":"2010","unstructured":"Sivanandam A, Murthy S, Kim SH, Barrack ER, Veer Reddy GP. Role of androgen receptor in prostate cancer cell cycle regulation: interaction with cell cycle regulatory proteins and enzymes of DNA synthesis. Curr Protein Pept Sci. 2010;11(6):451\u20138.","journal-title":"Curr Protein Pept Sci"},{"issue":"8","key":"5319_CR41","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1134\/S0006297920080039","volume":"85","author":"ES Shilkin","year":"2020","unstructured":"Shilkin ES, Boldinova EO, Stolyarenko AD, Goncharova RI, Chuprov-Netochin RN, Smal MP, Makarova AV. Translesion DNA Synthesis and Reinitiation of DNA Synthesis in Chemotherapy Resistance. Biochem (Mosc). 2020;85(8):869\u201382.","journal-title":"Biochem (Mosc)"},{"issue":"12","key":"5319_CR42","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/s43018-024-00848-4","volume":"5","author":"Y Yang","year":"2024","unstructured":"Yang Y, Badura ML, O\u2019Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, et al. Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer. Nat Cancer. 2024;5(12):1885\u2013901.","journal-title":"Nat Cancer"},{"issue":"2","key":"5319_CR43","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.cell.2020.11.042","volume":"184","author":"JZ Shen","year":"2021","unstructured":"Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, et al. FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells. Cell. 2021;184(2):352\u2013e369323.","journal-title":"Cell"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05319-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05319-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05319-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:45:19Z","timestamp":1785714319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05319-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5319"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05319-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable (this study did not involve human participants or animals).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1101"}}